EFFECT OF HYPOXIA ON THE LIFE OF TUMOR CELLS AND ITS CORRECTION BY CHEMICAL AGENTS AND DRUGS


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

In recent years, it is shown that hypoxia is one of the important triggers for tumor formation from genetically transformed cells. Hypoxia induces an activation of nuclear receptor, acting as a cellular oxygen sensor - hypoxia-inducible factor. The review discusses a theoretical background, experimental data and assumptions that the number of agents and drugs that enhance oxygen supply, hinder stabilization and increase the level of hypoxia-inducible factor may potentially inhibit the proliferation of tumor cells and their metastasis.

Texto integral

Acesso é fechado

Sobre autores

E. Astashkin

SRC SBEI HPE «First MSMU n.a. I.M. Sechenov» of RMH

Email: ast-med@mail.ru
Doctor of Biological Scineces, Prof. at the Department of Pathology, Head of the Laboratory of Extreme Conditions Moscow

Bibliografia

  1. Croce C.M. Oncogenes and cancer. N. Engl. J. Med. 2008;358(5):502-11.
  2. McCubrey J.A., Steelman L.S., Abrams S.L., Misaghian N, Chappell W.H., Basecke J., et al. Targeting the cancer initiating cell: the ultimate target for cancer therapy. Curr. Pharm. Des. 2012;18(13):1784-95.
  3. Yokota J. Tumor progression and metastasis. Carcinogenesis. 2000;21(3):497-503.
  4. Kunz M., Ibrahim S.M. Molecular responses to hypoxia in tumor cells. Mol. Cancer. 2003;2:23.
  5. Pham-Huy L.A., He H., Pham-Huy C. Free Radicals, Antioxidants in Disease and Health. Int. J. Biomed. Sci. 2008;4(2):89-96.
  6. Helmlinger G, Yuan F., Dellian M., Jain R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: High resolution measurements reveal a lack of correlation. Nat Med. 1997;3:177-82.
  7. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nature Rev. Cancer, 2002;2:38-47.
  8. Coleman C.N., Mitchell J.B., Camphausen K. Tumor hypoxia: chicken, egg, or a piece of the farm? J. Clin. Oncol. 2002;20:610-15.
  9. Krock Br.L, Skuli N., Celeste S.M. Hypoxia-Induced Angiogenesis:Goode and Evil. Genes& Cancer. 2011;2(12):1117-33.
  10. Abbruscato T.J., Davis T.P. Protein expression of brain endothelial cell E-cadherin after hypoxia/ aglycemia: influence of astrocyte contact. Brain Res. 1999;842:277-86.
  11. GraeberT.G,OsmanianC.,JacksT,HousmanD.E, Koch C.J., Lowe S.W. Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 1996;379:88-91.
  12. Chiche J., Rouleau M., Gounon P., Brahimi-Horn M.C., Pouyssegur J., Mazure N.M. Hypoxic enlarged mitochondria protect cancer cells from apoptotic stimuli. J. Cel.l Physiol. 2010; 222(3):648-57.
  13. Harrison L.R., Micha D., Brandenburg M., Simpson K.L., Morrow C.J., Denneny O., Hodgkinson C, Yunus Z., Dempsey C., Roberts D., Blackhall F., Makin G., Dive C. Hypoxic human cancer cells are sensitized to BH-3of the Bcl-2 protein Mcl-1. J. Clin. Invest. 2011;121(3):1075-87.
  14. Laderoute K.R., Mendonca H.L., Calaoagan J.M., Knapp A.M., Giaccia A.J., Stork P.J.S. Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironment. J. Biol. Chem. 1999;274:12890-97.
  15. Kunz M., Ibrahim S., Koczan D., Thiesen H.J., Koehler H.J., Acker T., Plate K.H., Ludwig S., Rapp U.R. Broecker E.B. Activation of c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) is critical for hypoxia-induced apoptosis of human malignant melanoma. Cell Growth Differ. 2001;12:137-45.
  16. Qiao D., Stratagouleas E.D., Martinez J.D. Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. Carcinogenesis. 2001;22(1):35-41.
  17. Cowan K.J., Storey K.B. Mitogen-activated protein kinases: new signaling pathways functioning in cellular responses to environmental stress. J. of Experimental Biology. 2003;206:1107-15.
  18. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 2004;30(2):193-204.
  19. Quintero M., Mackenzie N., Brennan P.A. Hypoxia-inducible factor 1 (HIF-1) in cancer. J. Surg. Oncol. 2004;30(5):465-68.
  20. Tal R. The role of hypoxia and hypoxia-inducible factor-1 alpha in preeclampsia pathogenesis. Biology Reproduction. 2012;87(6):1-8.
  21. Garber K. Energy boost: The Warburg effect returns in a new theory of cancer. J. Natl. Cancer Inst. 2004;96:1805-806.
  22. Hasebe Y., Egawa K., Yamazaki Y., Kunimoto S., Hirai Y., Ida Y., Nose K. Specific inhibition of hypoxia-inducible factor (HIF)-1 alpha activation and of vascular endothelial growth factor (VEGF) production by flavonoids. Biol. Pharm. Bull. 2003;26(10):1379-83.
  23. Jones D.T., Harris A.L. Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Mol. Cancer Ther. 2006;5(9):2193-202.
  24. Fong.G-H., Takeda K. Role and regulation of prolyl hydroxylase domain proteins. Cell Death and Differentiation. 2008;15:635-41.
  25. Buchmayer F., Pleiner J., Elmlinger M.W., Lauer G., Nell G., Sitte H.H. Actovegin: a biological drug for more than 5 decades. Wien Med. Wochenschr. 2011;161(3-4):80-8.
  26. Machicao F., Muresanu D.F., Hundsberger M.H., Pfluger M., Guekht A. Pleiotrophic neuroprotective and metabolic effects of Actovegin's mode of action. J. Neurol. Sci. 2012;322 (1-2):222-27.
  27. Elmlinger M.W., Kriebel M., Ziegler D. Neuroprotective and antioxidativeeffects of the hemodialysate actovegin on primary rat neurons in vitro. Neuromol. Med. 2011;13(4):266-74.
  28. Асташкин Е.И., Глезер М.Г., Винокуров М.Г., Егорова Н.Д., Орехова Н.С., Новикова А.Н., Грачев С.В., Юринская М.М., Соболев К.Э. Актовегин снижает уровень АФК в образцах крови пациентов с сердечной недостаточностью и уменьшает некроз нейтробластомных клеток человека линии SK-N-SH. Доклады Академии наук. 2013;448(2):232-35.
  29. Асташкин Е.И., Глезер М.Г., Винокуров М.Г., Орехова Н.С., Егорова Н.Д., Новикова А.Н., Юринская М.М., Грачев С.В., Соболев К.Э. Новые подходы к регуляции активности фагоцитов крови и снижение образования радикалов кислорода у пациентов с сердечной недостаточностью. Вестник РАМН. 2014;7-8:100-5.
  30. Юринская М.М., Винокуров М.Г., Асташкин Е.И., Грачев С.В., Орехова Н.С., Новикова А.Н., Соколова И.Н. Снижение нейротоксического эффекта пероксида водорода в эксперименте на перевиваемых нейронах человека при действии гемодиализата крови телят. Вестник Российской академии медицинских наук. 2014;9-10:10-4.
  31. Юринская М.М., Асташкин Е.И., Грачев С.В., Винокуров М.Г. Актовегин защищает клетки нейробластомы человека SK-N-SH от апоптоза, индуцированного пероксидом водорода через сигнальные пути PI-3K2011;161(3-4):80-8.
  32. Kuninaka T., Senga Y., Senga H., Weiner M. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. J. Cell Physiol. 1991;146(1):148-55.
  33. Hoyer S., Betz K. Elimination of the delayed postischemic energy deficit in cerebral cortex and hyppocampus of aged rats with a dried, deproteinized blood extract (Actovegin). Arch. Gerontol. Geriatr. 1989;9(2):181-92. и p38MAPK. Биологические мембраны. 2015;32(5-6):455-60.
  34. Reichel H., Weiss C., Leichtweiss H.P. The effects of a blood extract on the oxygen uptake of isolated artificially perfused kidneys and skeletal muscles in rats. Arzneim Forsch. 1965;15(756):757.
  35. Buchmayer F., Pleiner J., Elmlinger M.W., Lauer G., Nell G., Sitte H.H. Actovegin: a biological drug for more than 5 decades. Wien Med. Wochenschr.
  36. Semenza G.L. Targeting HIF-1 for cancer therapy. Nature Reviews Cancer. 2003;3:721-32.
  37. Zhang Q., Tang X., Lu Q.Y., Zhang Z.F., Brown J., Le A.D. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1A and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol. Cancer Ther. 2005;4(10):1465-74.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2016

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies